摘要
目的:探讨胰凝乳蛋白酶样蛋白酶体(chymotrypsin-like proteasome,CLP)活性作为前列腺癌生物标志物的可行性。方法:检测在体和离体的蛋白酶体活性,同时检测核因子κB的抑制蛋白α(inhibitory protein α of nuclear factorκB,IκB-α)、Bcl-2相关X蛋白(BCL-2 associated X protein,Bax)和细胞周期蛋白依赖性激酶抑制因子(cyclin-dependent kinase inhibitor,p27)的表达。结果:与正常前列腺上皮细胞及对照小鼠前列腺组织相比,前列腺癌细胞和前列腺肿瘤异种移植物中蛋白酶体底物蛋白IκB-α、Bax和p27的表达水平降低,CLP的离体和在体活性分别升高70%和23%。结论:CLP的活性可能是一种潜在的前列腺癌生物标志物,可能适合前列腺特异性抗原(prostate-specific antigen,PSA)在前列腺癌诊断中的补充。
Objective To investigate the feasibility of chymotrypsin-like proteasome(CLP)activity as a biomarker for prostate cancer.Methods Proteasome activity was determined in vitro and in vivo.We also measured the expression of inhibitory proteinαof nuclear factorκB(IκB-α),Bcl-2 associated X protein(Bax),and cyclin-dependent kinase inhibitor(p27).Results CLP activity was elevated by 70%in vitro and 23%in vivo,and the expression levels of the proteasome substrate proteins IκB-α,Bax,and p27 decreased in prostate cancer cells and prostate tumor xenografts compared with normal prostate epithelial cells and control mouse prostate tissue.Conclusion CLP activity is a potential biomarker for prostate cancer and may be used to supplement prostate-specific antigen in clinical diagnosis of prostate cancer.
作者
曾维威
赵永斌
李煜罡
刘为池
周宇辰
刘其炼
曾京华
Zeng Weiwei;Zhao Yongbin;Li Yugang;Liu Weichi;Zhou Yuchen;Liu Qilian;Zeng Jinghua(Department of Urology,Integrated Hospital of Traditional Chinese Medicine,Southern Medical Universit)
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2023年第8期903-908,共6页
Journal of Chongqing Medical University
